We use non-essential cookies (including anonymous analytics) to help us understand if our website is working well and to learn what content is most useful to visitors. We also use some cookies which are essential for our platform to work and help us to provide you with the best experience possible. You can accept or reject our non-essential cookies and change your mind at any time. To learn more, please read our cookies policy.

Update cookie preferences

New drug approved for ovarian cancer in Scotland

07 November 2016

The Scottish Medicines Consortium (SMC) has today approved the use of olaparib, by NHS Scotland, as a routine relapsed ovarian cancer treatment for women with a BRCA gene mutation.

The approval marks the first time the drug has been recommended to be routinely funded on the NHS.

In England and Wales olaparib is only available to patients facing cancer for the third time. This means a number of patients who would benefit still won't be able to access the drug.

Katherine Taylor, Chief Executive of research charity Ovarian Cancer Action, said: “The SMC’s decision to approve the routine use of olaparib is great news for patients in Scotland but begs the question – why is the rest of the UK falling behind? Why the postcode lottery?

“All women with ovarian cancer deserve the right to access to effective, proven treatments. The NHS now needs to make this treatment available to all of the patients who so desperately need it.”

Visit our BRCA hub to find out more about BRCA gene mutations.